KALA BIO Inc., a clinical-stage biopharmaceutical company headquartered in Arlington, United States, operates within the Health Care sector, specifically in the Pharmaceuticals industry. The company is publicly traded on the Nasdaq stock exchange under the ticker symbol KALA. As of January 1, 2026, KALA BIO’s closing stock price was $0.621, reflecting a significant decline from its 52-week high of $20.60, achieved on September 16, 2025. Conversely, the stock reached a 52-week low of $0.51 on December 17, 2025. This substantial price fluctuation indicates a notable discount from its historical peak, while the limited range between the high and low suggests constrained downside volatility in recent trading periods.
KALA BIO Inc. specializes in the development of proprietary drug delivery technologies aimed at permeating mucosal tissues, including those in the eyes, lungs, gastrointestinal tracts, and female reproductive systems. The company markets its innovative products on a global scale, leveraging its expertise in biopharmaceuticals to address complex medical challenges.
The company’s market capitalization stands at approximately $6,664,233 USD, with a price-to-earnings (P/E) ratio of -0.105, indicating that the company is not currently generating profits. This financial metric underscores the speculative nature of the stock, as investors may be anticipating future growth and profitability based on the company’s developmental pipeline and technological advancements.
KALA BIO Inc. made its Initial Public Offering (IPO) on July 20, 2017, marking its entry into the public market. Since then, the company has focused on advancing its clinical-stage projects and expanding its market presence. As of January 5, 2026, KALA BIO has reported no new developments. The most recent public communication, dated December 24, 2025, was mentioned in a Benzinga article that highlighted Indaptus Therapeutics’ 64% after-hours jump, with KALA being referenced in the same context.
For further information, stakeholders and interested parties can visit KALA BIO’s official website at www.kalarx.com . The company’s ongoing efforts in drug delivery technology continue to position it as a noteworthy entity within the biopharmaceutical landscape, despite the current financial metrics and stock performance challenges.
